Melhora da taxa de recaída e o tempo até recaída com uso de ublituximabe em pacientes com esclerose múltipla recorrente (EMR)

Referência

1. Steinman, L., Fox, E., Hartung, HP., Alvarez, E., Qian, P., Wray. S., Robertson, D., Huang, D., Selmaj, K., Wynn. D., Weiss, MS., Bosco, J.A., Power, S.A.,, Mok, K., Lee, L., Cree, B. (2022). Relapse Rate and Time to First Relapse Were Improved With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients With Relapsing Multiple Sclerosis (RMS). https://index.mirasmart.com/aan2022/PDFfiles/AAN2022-001011.html